new solid nodules detected in women and men. Method: In the randomized Dutch-Belgian Lung Cancer Screening (NELSON) Trial, 7,557 participants (16% female) underwent baseline screening. Three incidence rounds took place after intervals of 1year, 2years and 2.5years respectively. We included participants with solid non-calcified nodules registered after baseline as new and not visible in retrospect on a previous screen. Continuous variables were compared using the ManneWhitney U test or student's t test and are presented as medians with interquartile range (IQR) or means with standard deviation (±) respectively. Nominal variables were compared using the chi-squared test. Result: In total, 699 participants (149 [21%] women, 550 [79%] men) with 1,130 new solid nodules (241 [21%] in women, 889 [79%] in men) were included. Eventually, 5.4% of women with a new solid nodule and 10.4% of men with a new solid nodule were diagnosed with lung cancer (P¼0.063), corresponding to 3.3% of new solid nodules being malignant in women and 6.5% being malignant in men (P¼0.060). The female participants were significantly younger than the male participants (58±5 years vs. 60±5 years, P¼0.008), while there was no significant difference in smoking pack-years (39 years vs. 39 years [IQR 30-52], P¼0.696). Comparing new nodule size at initial detection in women and men, there was a significant difference for benign new nodules (51mm 3 , IQR: 29-128mm 3 vs. 66mm 3 , IQR: 35-177mm 3 , P¼0.019), but not for lung cancers (449mm 3 , IQR: 52-1050mm 3 vs. 447mm 3 , IQR: 196-1135mm 3 , P¼0.553). The currently advocated cutoff of 30mm 3 (about 3.9mm) reached >95% sensitivity in both genders. At first follow-up after detection, new solid nodules in women had resolved significantly more frequent than in men (69% vs. 58%, P¼0.003). Adenocarcinomas were significantly more common in women than in men (88% of lung cancers vs. 31% of lung cancers, P¼0.002), whereas the stage I detection rate was comparable (67% of lung cancers vs. 63% of lung cancers, P¼0.789). Conclusion: While there are significant differences between new solid nodules detected after baseline in women and men, there is no indication for a sex specific nodule management approach in LDCT lung cancer screening.
P2.11-03 Cardiovascular Risk Prediction in a Community-Based Lung Cancer Screening Programme H. Balata, M. Evison, R. Booton, P. Crosbie North West Lung Centre, Manchester University NHS Foundation Trust, Manchester/GB Background: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in populations eligible for lung cancer screening. The aim of this study was to determine whether a brief CV risk assessment, delivered as part of a community-based lung cancer screening programme, was effective in identifying individuals at high risk who might benefit from primary prevention. Method: The Manchester Lung Screening Pilot consisted of annual low dose CT (LDCT) over 2 screening rounds, targeted at individuals in deprived areas at high risk of lung cancer (age 55-74 and 6-year risk 1.51%, using PLCO M2012 risk model). All participants of the second screening round were eligible to take part in the study. Ten-year CV risk was estimated using QRISK2 in participants without CVD and compared to age (±5 years) and sex matched Health Survey for England (HSE) controls; high risk was defined as QRISK2 score 10%. Coronary artery calcification (CAC) was assessed on LDCT scans and compared to QRISK2 score. Result: Seventy-seven percent (n[920/1,194) of screening attendees were included in the analysis; mean age 65.6±5.4 and 50.4% female. QRISK2 and lung cancer risk (PLCO M2012 ) scores were correlated (r¼0.26, p<0.001). Median QRISK2 score was 21.1% (IQR 14.9-29.6) in those without established CVD (77.6%, n¼714/920), double that of HSE controls (10.3%, IQR 6.6-16.2; n¼714) (p<0.001). QRISK2 score was significantly higher in those with CAC (p<0.001). Screening attendees were 10-fold more likely to be classified high risk (OR 10.2 [95% CI 7.3-14.0]). One third (33.7%, n¼310/920) of all study participants were high risk but not receiving statin therapy for primary CVD prevention. Conclusion: Opportunistic CVD risk assessment within a lung cancer screening programme is feasible and is likely to identify a very large number of individuals suitable for primary prevention. Background: Implementing Low-Dose Computed Tomography screening for lung cancer will lead to an increased detection of early stages. The required resources to treat those cancers remains unknown. Method: We extended a well-established microsimulation model with data from the National Cancer Database to assess the number of lung cancer patients requiring surgery, radiotherapy, chemotherapy, and no therapy when implementing lung cancer screening in the United States in 2018. Three screening policies were assessed: the United States Preventive Task Force (USPSTF) recommendations; the Centers for Medicare and Medicaid Services (CMS) recommendations; and the most cost-effective policy from a study for Cancer Care Ontario (annual screening, ages 55-75, at least 40-pack year smoking history, currently smoking or quit within last 10 years). Base-case screening adherence was 50%. Sensitivity analyses assessed 20%, 35%, 65% and 80% adherence. Result: Implementing the USPSTF recommendations with 50% screening adherence would require 35.3% more lung cancer surgeries in 2015-2040 compared to no screening. However, 2.1% less radiotherapy and 5.1% less chemotherapy treatments would be required. Furthermore, 6.2% fewer patients would receive no therapy. The required number of lung cancer surgeries would be 75,379 in 2018, 58,155 in 2023, 55,269 in 2028, and 45,007 in 2040 . Compared to no screening, this is an increase of 92.7% in 2018, 44.3% in 2023, 36.8% in 2028, and 23 .0% in 2040. Screening adherence strongly influenced results. By 2018, the required number of surgeries would range from 53,666 (with 20% adherence) to 96,953 (with 80% adherence). Results for the CMS and Ontario policies were similar to the USPSTF policy, although changes compared to no screening were smaller. Conclusion: Implementing lung cancer screening in the United States requires a major increase in surgical capacity. The current workforce of thoracic surgeons in the United States may not be able to cope with this increased demand. Recruitment strategies were developed to recruit individuals through provider and community-led recruitment strategies and emphasized supporting equitable access to screening through targeted recruitment activities. A major aim of the pilot is recruiting highest risk individuals who are known to have the highest rates of cigarette smoking: lower socioeconomic status (SES) and First Nations, Inuit and Metis (FNIM). Method: CCO supported the development and use of multi-component strategies built upon findings from an internal literature review. Strategies were used to recruit potentially eligible screening participants,
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